Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

A Look into the Future of Chronic Pain Management

An Interview with Innocan Pharma’s CEO, Iris Bincovich. Innocan Pharma is gaining attention for its innovative pain relief solutions — particularly through its slow-release injection technology. This cutting-edge approach delivers synthetic Cannabidi...

A Topical Solution for Chronic Pain

Pain impedes the life of millions around the world, and the market for topical creams to treat this pain is growing at an accelerated rate as people choose to treat pain directly vs ingesting pain killers. Some analysts, such as those at Allied Market Research, project that ...

A ‘Barrier’ to Better Health

(Click image to play podcast) The blood-brain barrier plays an essential role in protecting the brain from blood-borne disease. But is also one of medicine’s great paradoxes – a system designed to protect the most sensitive region of the body bu...

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...

Buzz on the Bullboards: The Top Last-Minute Movers of 2021

Expecting the markets to be relaxed heading into the holidays? Hardly. Many investors and brokers know that this is the time to shine. With every twist and turn the global economy has been throwing our way, the right move is staying active. This past week, it seems ma...

Buzz on the Bullboards: Investor caution impacts market activity

The TSX began the week on a high note, buoyed by strength in the financial and industrial sectors. However, by Tuesday, the market had slipped into the red, as investor caution took hold ahead of the upcoming U.S. inflation data. Luckily for investors, things rebounded si...

VIDEO: FSD Pharma CEO Raza Bokhari updates investors on ‘HUGE’ news

FSD Pharma Inc. ( CSE: HUGE , OTCQB: FSDDF , Forum ) is focused on the research and development of novel cannabinoid-based treatments for several central nervous system disorders including chronic pain, fibromyalgia and irritable bowel syndrome, and on the deve...

Zynex Shares Trade Higher After Reporting a 95% Increase in Q3 Orders

Non-invasive medical device maker Zynex Inc's. shares are trading 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018. This morning medical technology company specializing in manufacturing and s...

Krill oil boom is real

There’s a new type of oil that’s causing a major stir in the markets. This oil boom has nothing to do with crude oil or energy though. But it still has the potential to be just as profitable. I’m talking about krill oil. ...

Covid 19: Will pain-free, at-home screening tests be our salvation?

The world’s best defence against the spread of COVID-19 in 2021 will not be a vaccine, medical experts now say. Instead, it will be the widespread adoption of cheap, non-invasive diagnostic detection devices for coronaviruses – ones that look and function...
1 2 3 4 5 6 7 8 9 10 ...